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Introduction
Hepatitis E is the infection of the liver caused by 
a virus known as the hepatitis E virus (HEV) and has 
posed severe public health hazards around the world. 
HEV has four major genotypes (1–4) that are glob-
ally distributed into different epidemiological patterns 
based on socioeconomic factors and ecology (Lu et al. 
2006). HEV genotypes 1 and 2 infect humans solely 
(Ahmad et al. 2011). Generally, genotype 1 accounts for 
the epidemics in some parts of Asia, while genotype 2 is 
more prevalent in Africa, Mexico, and other developing 
countries (Colson et al. 2012). Genotypes 3 and 4 are 
zoonotic with an expanded host range (Okamoto 2007), 
while there have been noted chronic HEV infections 
in immunosuppressed patients (Honer zu Siederdissen 
et al. 2014). Genotype 3 is prevalent worldwide, while 
genotype 4 is mainly present in Asia. Besides, geno-
types 5 and 6, which primarily infect wild boar, have 
been found in Japan (Sato et al. 2011; Takahashi et al. 
2011). Recently, new genotypes, known as HEV-7 and 
HEV-8, were also found to infect camels and humans 
(Al-Sadeq et al. 2017).
Currently, HEV’s diagnosis depends on specific 
serological and nucleic acid tests, as the clinical mani-
festations and routine laboratory measures of HEV are 
similar to those of other acute hepatitis (Zhang et al. 
2019). There are four major methods for diagnosing 
hepatitis E, including the detection of anti-HEV IgM 
and IgG antibodies, the antigen (Ag), and HEV RNA. 
Presently, the clinical diagnosis of acute hepatitis  E 
cases mainly depends on the serological detection of 
anti-HEV antibodies (Dreier and Juhl 2014). However, 
equivalence, sensitivity, and specificity in the results 
of the HEV Enzyme-linked Immunosorbent Assay 
(ELISA) kits tend to differ between manufacturers, lead-
ing to discrepancies in the rates of anti-HEV antibod-
ies among different populations (Herremans et al. 2007; 
Drobeniuc et al. 2010), together with the HEV genome 
heterogeneity, and the different antigenic structure 
Performance Evaluation of Different Commercial Serological Kits
for Diagnosis of Acute Hepatitis E Viral Infection
QIANG ZHANG1*, XIAOLONG ZONG2, DONGMING LI3, JING LIN1 and LIHUA LI1
1 Department of Clinical Laboratory, Branch of Tianjin Third Central Hospital, Tianjin, China
2 Department of Clinical Laboratory, The Second Hospital of Tianjin Medical University, Tianjin, China
3 Department of Clinical Laboratory, Tianjin Third Central Hospital, Tianjin, China
Submitted 7 March 2020, revised 4 May 2020, accepted 9 May 2020
A b s t r a c t
Clinical diagnosis of hepatitis E viral (HEV) infection mainly relies on serological assays, and the current status of misdiagnoses regarding 
HEV infection is uncertain. In this study, patients with acute HEV infection were tested for anti-HEV IgM and IgG, a HEV antigen (Ag), 
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a substantial agreement, but the Kehua and Genelabs tests were more specific than the Wantai and Lizhu tests. The Wantai tests for the HEV 
Ag and HEV RNA were also important for acute HEV infections (Kappa = 0.787). Furthermore, a total of 6.98% of HEV infections were 
positive for HEV RNA but negative for both the HEV Ag and anti-HEV antibodies of IgM and IgG classes. Our findings demonstrate that 
the diagnosis of hepatitis E may be missed if only serological assays are used. Thus, a combination of serological and nucleic acid testing 
provides the optimal sensitivity and specificity to the diagnostic process.
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of HEV proteins. Moreover, cross-reactions of anti-
HEV IgM with the Epstein-Barr virus (EBV) and cyto-
megalovirus (CMV) antibodies have been reported, 
which cause false-positive results (Hyams et al. 2014). 
Currently, the development of the HEV RNA assay kits 
is in the early stages in China and has not yet been 
widespread. Thus, the clinical diagnosis of HEV infec-
tion still mainly relies on serological assays with a few 
reports of hepatitis E misdiagnoses occurring in China.
In the present study, the performance of four com-
mercial serological assays and PCR assay for the detec-
tion of HEV infection was evaluated, and the possibil-
ity of misdiagnosing of this infection using serological 
detection alone was determined.
Experimental
Materials and Methods
Samples. From March 2014 to March 2018, 364 
serum samples were collected from Tianjin Third Cen-
tral Hospital and Tianjin Medical University General 
Hospital. A total of 86 cases were diagnosed with acute 
viral hepatitis E (Kamar et al. 2014; European Asso-
ciation for the Study of the Liver 2018), 91 cases with 
rheumatic diseases (RD) including systemic lupus ery-
thematosus (SLE) and rheumatoid arthritis (RA), and 
91 cases with viral hepatitis by CMV or EBV according 
to the diagnostic guidelines of each disease. Meanwhile, 
96 healthy volunteers were included in this study. Five 
milliliters of venous blood was collected and aggluti-
nated for 10 min at 37°C, and subsequently centrifuged 
at 3,000 × g for 15 min at 4°C. The serum was taken and 
stored at –80°C before analysis. This study received 
approval from the Branch of Tianjin Third Central Hos-
pital Ethics Committee (2019028). Our study was non-
interventional and did not involve any specific sampling 
or addition to the usual procedures. An anonymized 
database provided analytical support. Therefore, the 
ethics committee waived the need for patient consent.
HEV serological assays. The commercially available 
HEV ELISA kits were selected with Wantai (Beijing, 
China), Kehua (Shanghai, China), Lizhu (Zhuhai, 
China), and Genelabs (Singapore, Singapore) for the 
detection of both IgM and IgG antibodies. For the HEV 
Ag assay, the Wantai was the only available commercial 
provider for the ELISA kit in China. All the experimen-
tal operations were performed according to the instruc-
tions recommended by manufacturers. Results of the 
ELISA tests were listed as ratios (s/co), and interpreta-
tions were made as advised in the instructions.
The HEV RNA assay. One-step reverse transcrip-
tion-quantitative polymerase chain reaction (RT-qPCR) 
assay was set up by our research team and had been 
approved for clinical use. Primers and probes were 
designed based on a multiple sequence alignment of the 
HEV genome sequences in the ORF3 region, and syn-
thesized by the Sangon Biotech Company (Shanghai, 
China): forward primer, 5’-GGTGGTTTCTGGGGT-
GAC-3’ (Tm = 61.2°C); reverse primer, 5’-AGGGGTTG-
GTTGGATGAA-3’ (Tm = 61.2°C); probe, 5’-TGATTC- 
TCAGCCCTTCGC-3’ (Tm = 62.5°C). NCBI-Primer-
BLAST searches for the primers and probe showed 
that the genetic sequences of the different HEV geno-
types 1–4 were highly conserved in the ORF3 region. 
Firstly, the target fragment of 70 bp was amplified from 
the strain of HEV genotype 4 (CHNXJ-SW13) by the 
forward and reverse primers mentioned above, and 
then inserted the fragment into Promega T-easy Vec-
tor (3105 bp) to obtain the standard plasmid. Serial 
dilutions plasmids of 5 × 100 ~ 5 × 109 copies/2 μl were 
obtained by 10-fold dilution, and the standard curve 
was established. Total RNA was extracted from 140 µl 
serum using TIANamp Virus RNA Kit (Tiangen, 
Beijing, China). The One-Step PrimeScript’ RT-PCR 
Kit (Takara, Dalian, China) enabled the performance 
of RT-qPCR in a total 20-µl reaction system, includ-
ing 10 µl GoTaq Probe qPCR Master Mix (1×), 0.4 µl 
GoScript RT Mix for one-step RT-qPCR (1×), 1 µl for-
ward primer (500 mM), 1 µl reverse primer (500 mM), 
0.5 µl probe (250 nM), 5.1 µl RNase-Free H2O and 2 µl 
RNA template or standard plasmid of HEV. Subse-
quently, the reaction was conducted with the MX3000P 
Real-Time QPCR System (Aligent, California, USA). 
The conditions for PCR amplification involved the fol-
lowing: 1 cycle at 45°C for 30 min, 1 cycle at 95°C for 
15 min, followed by 45 cycles at 95°C for 10 sec, at 55°C 
for 20 sec and at 72°C for 15 sec. The expression of the 
HEV RNA was calculated according to the standard 
curve established by plasmids with different dilutions.
Data analysis. Commercially available software was 
used for all the statistical analyses (MedCalc, version 
18.2, Belgium). The receiver operating characteristic 
(ROC) curve was used to analyze the diagnostic per-
formances for anti-HEV IgG and IgM assays. Agree-
ments between different kits were assessed by the 
Kappa statistic. The level of agreement was defined 
by the Kappa coefficient as excellent (> 0.8), substan-
tial (0.6–0.8), moderate (0.4–0.6), fair (0.2–0.4), and 
poor (< 0.2) (Nogues-Sabate et al. 2018). A p-value of 
less than 0.05 was considered statistically significant. 
Additionally, two-sided 95% confidence intervals (CI) 
were calculated.
Results
Performance of anti-HEV IgM assays. The diag-
nostic performance characteristic of each anti-HEV 
IgM kit was determined by the ROC curve. As shown 
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in Table  I, the area under the curve (AUC) value of 
the ELISA kits ranged from 0.909 to 0.93. The sensitiv-
ity among the 86 acute HEV infections ranged from 
82.6% to 86% (Table I), suggesting an excellent agree-
ment (Kappa: 0.819–1) in anti-HEV IgM antibody 
detection between the ELISA kits (Table  II). All the 
anti-HEV IgM assays evaluated demonstrated good 
specificities (97.8–100%), except for two false-positive 
results obtained from the RD cases detected by the 
Genelabs ELISA kit. No positive results were shown in 
CMV/EBV infected patients by all the assays (Table I), 
which demonstrated that there were no cross-reactions 
of IgM against CMV and EBV.
Performance of anti-HEV IgG assays. The AUC 
value (0.827–0.929) of the four distinct anti-HEV 
IgG kits are shown in Table III. The sensitivity among 
the acute HEV infection patients ranged from 87.2% 
to 91.9% and showed a substantial agreement with 
Kappa coefficients from 0.752 to 0.927 between each 
different ELISA kit (Table III and IV). However, the 
specificities of anti-HEV IgG among the non-HEV 
population showed significant inconsistency between 
each ELISA kit (Table IV). The specificity of the Kehua 
(96.9–98.9%) and Genelab (96.7–98.9%) tests were 
significantly higher when compared with the Wantai 
(64.6–81.3%) and Lizhu assays (69.8–83.5%) (Table III).
The HEV Ag and HEV RNA assays. A total of 
36 acute HEV patients were positive for the HEV Ag 
Wantai 84.9 100 100 95.5 0.924  100 100 100
 (75.5–91.7) (98.7–100) (100–100) (92.8–97.2) (0.892–0.949) < 0.01 (100–100) (100–100) (100–100)
Kehua 86.0 100 100 95.9 0.930  100 100 100
 (76.9–92.6) (98.7–100) (100–100) (93.2–97.5) (0.899–0.954) < 0.01 (100–100) (100–100) (100–100)
Lizhu 83.7 100 100 95.2 0.919  100 100 100
 (74.2–90.8) (98.7–100) (100–100) (92.5–97.0) (0.886–0.945) < 0.01 (100–100) (100–100) (100–100)
Genelabs 82.6 99.3 97.3 94.8 0.909  97.8 100 100
 (72.9–89.9) (97.4–99.9) (89.9–99.3) (92.1–96.7) (0.875–0.937) < 0.01 (94.8–100) (100–100) (100–100)
Table I
Diagnostic performance of anti-HEV IgM assays.
Com-
mercial
tests
%
Sensitivity
(95% CI)
%
Specificity
(95% CI)
%
PPV
(95% CI)
%
NPV
(95% CI)
AUC
(95% CI) p
%
Specificity
with
RD
(95% CI)
%
Specificity
with
CMV/EBV
(95% CI)
%
Specificity
with
healthy
(95% CI)
Wantai
Kehua 98.8 0.950 (0.852–1.000)
Lizhu 98.8 0.953 (0.862–1.000)
Genelabs 95.3 0.819 (0.648–0.990)
Kehua
Lizhu 97.7 0.903 (0.771–1.000)
Genelabs 96.5 0.860 (0.706–1.000)
Lizhu
Genelabs 96.5 0.868 (0.722–1.000)
Table II
Concordance for anti-HEV IgM assays in the diagnosis
of the acute HEV infections.
Commercial
tests
%
Concordance
Kappa
(95% CI)
Wantai 91.9 74.8 53.0 96.7 0.833  79.2 81.3 64.6
 (83.9–96.7) (69.3–79.8) (47.7–58.3) (93.6–98.4) (0.791–0.870) < 0.01 (71.0–87.3) (73.3–89.3) (55.0–74.1)
Kehua 87.2 97.5 91.5 96.1 0.923  98.9 97.8 96.9
 (78.3–93.4) (94.9–99.0) (83.7–95.7) (93.4–97.7) (0.891–0.949) < 0.01 (96.6–100) (94.8–100) (93.4–100)
Lizhu 89.5 75.9 53.5 95.9 0.827  83.5 74.7 69.8
 (81.1–95.1) (70.4–80.8) (48.0–58.9) (92.6–97.8) (0.784–0.865) < 0.01 (75.9–91.1) (65.8–83.6) (60.6–79.0)
Genelabs 88.4 97.5 91.6 96.4 0.929  98.9 96.7 97.9
 (79.7–94.3) (94.9–99.0) (83.9–95.8) (93.8–98.0) (0.898–0.953) < 0.01 (96.6–100) (93.0–100) (95.0–100)
Table III
Diagnostic performance of anti-HEV IgG assays.
Com-
mercial
tests
%
Sensitivity
(95% CI)
%
Specificity
(95% CI)
%
PPV
(95% CI)
%
NPV
(95% CI)
AUC
(95% CI) p
%
Specificity
with
RD
(95% CI)
%
Specificity
with
CMV/EBV
(95% CI)
%
Specificity
with
healthy
(95% CI)
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using the Wantai ELISA kit, with no positive cases 
found among the non-HEV infection patients. A total 
of 44  acute HEV infection patients were positive for 
HEV RNA. The consistency rate between the HEV Ag 
and RNA was 90.7% (78/86), as shown in Table V. The 
two methods had a substantial agreement with a Kappa 
coefficient of 0.787 (0.656–0.918). Furthermore, six of 
the 86 samples were positive for HEV RNA but negative 
for anti-HEV IgM and IgG antibodies, and the HEV Ag 
by all ELISA kits (Fig. 1).
Discussion
To date, the identification of serological markers in 
HEV infections using accurate diagnostic assays remain 
a  challenge. There are a plethora of issues regarding 
the specificity and sensitivity of HEV serological assays 
in epidemiological and clinical settings that require 
urgent attention. In this present study, we evaluated 
four dominant, commercially available anti-HEV IgM 
and IgG assays, as well as the HEV Ag and HEV RNA 
to investigate the misdiagnosis’s current status rely on 
the current measurements.
Anti-HEV IgM appears in the early phase of acute 
hepatitis E. The antibodies can be detected as early as 
four days after the onset of jaundice and last up to five 
months (Kuniholm et al. 2009). There are two main 
methods in anti-HEV IgM serological assays: the cap-
ture method with anti-human IgM μ chain (Wantai, 
Kehua and Lizhu), and the indirect method (Genel-
abs). The sensitivity and specificity of different meth-
Table IV
Concordance for anti-HEV IgG assays.
Com-
mercial
tests
Concordance of HEV Concordance of RD Concordance of CMV/EBV Concordance of healthy
% Kappa (95% CI) % Kappa (95% CI) % Kappa (95% CI) % Kappa (95% CI)
Wantai
Kehua 95.3 0.753 (0.524–0.982)  80.2 0.081 (–0.069–0.231) 81.3 0.069 (–0.102–0.239) 68.8 0.147 (0.015–0.279)
Lizhu 98.8 0.927 (0.785–1.000)  91.2 0.712 (0.525–0.898) 88.5 0.809 (0.664–0.954) 94.8 0.882 (0.782–0.982)
Genelabs 96.5 0.805 (0.592–1.000)  80.2 0.081 (–0.069–0.231) 82.4 0.153 (–0.064–0.369) 67.7 0.111 (–0.007–0.229)
Kehua
Lizhu 96.5 0.823 (0.629–1.000)  84.6 0.107 (–0.087–0.300) 76.9 0.125 (–0.034–0.283) 74.0 0.183 (0.238–0.341)
Genelabs 96.5 0.837 (0.658–1.000) 100 1.000 (1.000–1.000) 98.9 0.795 (0.403–1.000) 99.0 0.852 (0.566–1.000)
Lizhu
Genelabs 95.3 0.752 (0.520–0.984)  84.6 0.107 (–0.087–0.300) 78.0 0.183 (0.001–0.366) 72.9 0.139 (–0.005–0.282)
HEV Ag +, n (%) 36 (41.86)  0 (0) 36 (41.86)
HEV Ag −, n (%)  8 (9.3) 42 (48.84) 50 (58.14)
Total, n (%) 44 (51.16) 42 (48.84) 86 (100)
Table V
Consistency for HEV Ag and HEV RNA assays in the diagnosis
of the acute HEV infections.
HEV RNA +,
n (%)
HEV RNA −,
n (%)
Total,
n (%)
Fig.1. Flow diagram for patients with acute viral hepatitis E.
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ods present variations in anti-HEV IgM assays with 
a  recent study demonstrating a high cross-reactivity 
of HEV IgM compared to EBV and CMV (Drobeniuc 
et al. 2010). However, in the present study, no false-pos-
itive results due to cross-reaction with EBV- or CMV-
infected patients were observed, indicating the highly 
specific nature of the anti-HEV IgM assays. Moreover, 
these findings were found to be consistent with those 
of the other groups, including immunocompromised 
patients (Abravanel et al. 2013) and infections with 
HEV genotype 3 (Legrand-Abravanel et al. 2009). The 
Genelabs ELISA kit detected two false-positive results 
obtained from patients with RD. This finding supports 
the opinion that the capture method using the anti-
human IgM μ chain is more specific than the indirect 
method using the anti-HEV IgM assay.
In general, the detection of anti-HEV IgG is usu-
ally used as an indicator of past infection. However, 
the appearance of the anti-HEV IgG antibody is early, 
which could be used in the clinical diagnosis of acute 
HEV infection (Aggarwal and Jameel 2011). The Qatar 
research group found that Wantai HEV-IgG assays 
revealed high sensitivity and specificity with excellent 
Kappa concordance using different enzyme immuno-
assays in assessing seroprevalence of HEV antibodies 
(Al-Absi et al. 2018). However, a significant discrepancy 
in anti-HEV IgG results between different assay kits in 
the non-HEV population was found in our study. The 
positive rates were significantly higher by the Wantai 
and Lizhu kits than those of Kehua and Genelabs. 
A Korean research compared anti-HEV IgG antibody 
results using the Genelabs and Wantai ELISA kits to 
estimate HEV serum prevalence in the Korean popula-
tion (Park et al. 2012). They found a significant incon-
sistency in the results between the two assays, which 
was also observed in our study. Therefore, epidemiolo-
gical investigations of HEV in the population may lead 
to significant inconsistencies when different kits are 
used. The Kehua and Genelabs IgG assays had high spe-
cificities in the non-HEV population and could be used 
in the clinical diagnosis of HEV. On the other hand, the 
Wantai and Lizhu IgG assays were more suitable for epi-
demiological investigations because the positive rates in 
the non-HEV population were too high to distinguish 
the acute HEV infection from the previous disease.
In this study, all four anti-HEV IgG serological 
assays used the indirect method. There are two major 
types of antigens coated on the plates for binding of 
anti-HEV IgG antibodies, including synthetic peptides 
and recombinant proteins (Innis et al. 2002; Ulanova 
et al. 2008). The use of the recombinant ORF2-encoded 
protein in numerous serological studies has revealed its 
significant efficacy in the identification of antibodies 
against various HEV strains (Christensen et al. 2008; 
Kuniholm et al. 2009). Since recombinant proteins can 
replicate the HEV neutralizing epitope better than the 
synthetic peptides, the results in the Wantai anti-HEV 
IgG assay were more sensitive. A French research group 
also substantiated that the Wantai IgG assay was the 
most sensitive amongst all other eight commercial 
ELISA kits used to detect HEV of genotypes 1 and 3 
(Abravanel et al. 2013). The results suggested that the 
anti-HEV IgM assay was superior in the diagnosis of 
acute HEV infection due to its good specificity when 
paired with the Wantai anti-HEV IgG assay, which 
could improve the accuracy of diagnosis.
The latest reports have indicated that this novel HEV 
Ag is a resourceful serum marker to detect the acute HEV 
infection and has a good consistency with HEV RNA 
(Zhang et al. 2006; Zhao et al. 2015; Fraga et al. 2018; 
Zhang et al. 2019). Our findings in this study also sup-
ported this view. However, all the HEV Ag positive 
samples showed positive anti-HEV IgM results (Fig. 1), 
which provided no direct evidence to support that Ag 
detection could improve diagnostic efficiency. Further-
more, six samples were only positive for HEV RNA but 
negative for anti-HEV IgM and IgG, as well as Ag in all 
ELISA kits employed, which showed that 6.98% of acute 
HEV infection patients have a chance to be misdiagnosed 
if reliant on serological assays detection alone. It indi-
rectly indicates that HEV RNA detection can improve 
diagnostic efficiency. However, despite the highly spe-
cific and sensitive capability of some PCR assays for the 
detection of HEV RNA, their utility has been restricted 
due to the short period of HEV viremia detection. 
Therefore, the incidence of acute HEV infection cannot 
be completely ruled out by a negative HEV PCR result.
In conclusion, for the successful diagnosis of acute 
viral hepatitis E, a combination of nucleic acid and 
serological tests is imperative to provide excellent speci-
ficity and sensitivity to the diagnosis. However, we also 
observed significant inconsistencies between the sero-
logical and HEV RNA assays; thereby, caution is war-
ranted while interpreting the results of both serological 
and molecular tests in HEV diagnosis.
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